TrialCompass TCL
Back to results
Phase 1, Phase 2RecruitingPriority 3 · Moderate priorityNCT07022964

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

ClinicalTrials.gov

Plain-language summary

This Phase 1, Phase 2 trial is testing CD5 CAR-T cells infusion for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 14 Years to 70 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

CD5 CAR-T cells infusion (DRUG): Approximately 3-5 days prior to CD5 CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.

Drugs / treatments
CD5 CAR-T cells infusion
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

NCT07022964

Phase: Phase 1, Phase 2 | Status: Recruiting | Priority: Medium

Plain-language summary

This Phase 1, Phase 2 trial is testing CD5 CAR-T cells infusion for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join

  • Age 14 Years to 70 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

CD5 CAR-T cells infusion (DRUG): Approximately 3-5 days prior to CD5 CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.

Drugs / treatments: CD5 CAR-T cells infusion

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 36 patients

Primary endpoint: Dose-limiting toxicity (DLT); Adverse events (AEs)

Ages: 14 Years to 70 Years

Start date: 2025-06-01 | Est. completion: 2028-06-01

Locations

0 US sites · 3 total

Contact

Haiyang LU, Ph.D | lhy13062@rjh.com.cn | 86+ 18221015770

Sponsor: Beijing GoBroad Hospital (OTHER)

Tags

CTCL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07022964

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.